… who have progressed on or after EGFR TKI therapy. In this review, we … EGFR inhibitors and
combination treatment strategies for treating patients with NSCLC harboring EGFR mutations …

… EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR
mutations… Besides, combination strategies based on EGFR TKIs in the first line treatment …

… To assess the clinical effectiveness of single‐agent or combination EGFR therapies used
in the first‐line treatment of people with locally advanced or metastatic EGFR M+ NSCLC …

… , treatment with targeted therapies results in superior outcomes compared with chemotherapy.
EGFR mutations … survival (PFS) benefit with EGFR tyrosine kinase inhibitor (TKI) treatment. …

… EGFR mutations may benefit from second-line EGFR TKI … arm received the planned second-line
therapy. Only a head-to-… activating EGFR mutation randomized to either first-line EGFR …

… F-TKIs in previously treated advanced EGFR-mutated NSCLC. … first-line treatment for
patients with advanced EGFR-mutated … evaluated first-line treatments in advanced EGFR-mutated …

… EGFR mutations as compared with those undergoing chemotherapy. Other meta-analyses
of treatment … OS benefit, in a population of mixed EGFR-activating mutations (Lee et al, 2013; …

… In certain regions testing at initial diagnosis for EGFR mutation remains quite low and
may occur at a rate of 22.6% for stage IV adenocarcinoma patients (37). When an …

… Areas covered: This review describes the EGFR pathway and its abnormalities … first and
next-generation EGFR TKIs in the first-line treatment of tumors with an activating EGFR mutation, …

… EGFR-TKI with another as first-line therapy in patients with advanced NSCLC whose tumors
present with an EGFR-activating mutation. … population associated with EGFR mutations, but …